1. BAT for HFrEF
Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control. They were followed for 6 months.
Results
(p = 0.002)
Primary safety outcome: Freedom from major adverse neurological and CV events in BAT arm: 97.2%
Primary efficacy outcomes for BAT vs. control: improved NYHA class: 55% vs. 24%, p = 0.002; 6-minute walk distance: 59.6 vs. 1.5 m, p = 0.004; Minnesota Living with HF QOL: vs. 2.1, p < 0.001 %
Conclusions
Results of this pilot trial indicate that among patients with chronic systolic HF, the addition of BAT to optimal medical therapy provides modest symptomatic benefit at 6 months, compared with optimal medical therapy alone
Larger studies, powered for clinical outcomes, are awaited
Primary endpoint
BAT
(n = 76)
Control
(n = 70)
Abraham WT, et al. JACC Heart Fail 2015;Mar 16:[Epub]